|
1
|
Halegoua-De Marzio D and Hann HW:
Prevention of hepatocellular carcinoma and its recurrence with
anti-hepatitis B viral therapy. Minerva Gastroenterol Dietol.
60:191–200. 2014.PubMed/NCBI
|
|
2
|
Brown ZJ, Hewitt DB and Pawlik TM:
Experimental drug treatments for hepatocellular carcinoma: Clinical
trial failures 2015 to 2021. Expert Opin Investig Drugs.
31:693–706. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fan W and Ye G: Microarray analysis for
the identification of specific proteins and functional modules
involved in the process of hepatocellular carcinoma originating
from cirrhotic liver. Mol Med Rep. 17:5619–5626. 2018.PubMed/NCBI
|
|
4
|
Sia D, Villanueva A, Friedman SL and
Llovet JM: Liver cancer cell of origin, molecular class, and
effects on patient prognosis. Gastroenterology. 152:745–761. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maucort-Boulch D, de Martel C, Franceschi
S and Plummer M: Fraction and incidence of liver cancer
attributable to hepatitis B and C viruses worldwide. Int J Cancer.
142:2471–2477. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Martel C, Maucort-Boulch D, Plummer M
and Franceschi S: World-wide relative contribution of hepatitis B
and C viruses in hepatocellular carcinoma. Hepatology.
62:1190–1200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yeh IJ, Liu KT, Shen JH, Wu YH, Liu YH,
Yen MC and Kuo PL: Identification of the potential prognostic
markers from the miRNA-lncRNA-mRNA interactions for metastatic
renal cancer via next-generation sequencing and bioinformatics.
Diagnostics (Basel). 10:2282020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Piasentin N, Milotti E and Chignola R: The
control of acidity in tumor cells: A biophysical model. Sci Rep.
10:136132020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chung C, Mader CC, Schmitz JC, Atladottir
J, Fitchev P, Cornwell ML, Koleske AJ, Crawford SE and Gorelick F:
The vacuolar-ATPase modulates matrix metalloproteinase isoforms in
human pancreatic cancer. Lab Invest. 91:732–743. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spennati G, Horowitz LF, McGarry DJ,
Rudzka DA, Armstrong G, Olson MF, Folch A and Yin H: Organotypic
platform for studying cancer cell metastasis. Exp Cell Res.
401:1125272021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tarbell J, Mahmoud M, Corti A, Cardoso L
and Caro C: The role of oxygen transport in atherosclerosis and
vascular disease. J R Soc Interface. 17:201907322020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Drenckhan A, Freytag M, Supuran CT, Sauter
G, Izbicki JR and Gros SJ: CAIX furthers tumour progression in the
hypoxic tumour microenvironment of esophageal carcinoma and is a
possible therapeutic target. J Enzyme Inhib Med Chem. 33:1024–1033.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hodge RG and Ridley AJ: Regulating Rho
GTPases and their regulators. Nat Rev Mol Cell Biol. 17:496–510.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bian R, Dang W, Song X, Liu L, Jiang C,
Yang Y, Li Y, Li L, Li X, Hu Y, et al: Rac GTPase activating
protein 1 promotes gallbladder cancer via binding DNA ligase 3 to
reduce apoptosis. Int J Biol Sci. 17:2167–2180. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Imaoka H, Toiyama Y, Saigusa S, Kawamura
M, Kawamoto A, Okugawa Y, Hiro J, Tanaka K, Inoue Y, Mohri Y and
Kusunoki M: RacGAP1 expression, increasing tumor malignant
potential, as a predictive biomarker for lymph node metastasis and
poor prognosis in colorectal cancer. Carcinogenesis. 36:346–354.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gu Y, Chen B, Guo D, Pan L, Luo X, Tang J,
Yang W, Zhang Y, Zhang L, Huang J, et al: Up-Regulation of RACGAP1
promotes progressions of hepatocellular carcinoma regulated by
GABPA via PI3K/AKT pathway. Oxid Med Cell Longev. 2022:30341502022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liao S, Wang K, Zhang L, Shi G, Wang Z,
Chen Z, Zhu P and He Q: PRC1 and RACGAP1 are diagnostic biomarkers
of early HCC and PRC1 Drives Self-Renewal of liver cancer stem
cells. Front Cell Dev Biol. 10:8640512022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pu J, Wang J, Wei H, Lu T, Wu X, Wu Y,
Shao Z, Luo C and Lu Y: lncRNA MAGI2-AS3 Prevents the Development
of HCC via Recruiting KDM1A and Promoting H3K4me2 Demethylation of
the RACGAP1 Promoter. Mol Ther Nucleic Acids. 18:351–362. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morris GM, Huey R and Olson AJ: Using
AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics
Chapter 8: Unit 8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vakser IA: Long-distance potentials: An
approach to the multiple-minima problem in ligand-receptor
interaction. Protein Eng. 9:37–41. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng D, Liu M, Liu Y, Zhao X, Sun H, Zheng
X, Zhu J and Shang F: Micheliolide suppresses the viability,
migration and invasion of U251MG cells via the NF-κB signaling
pathway. Oncol Lett. 20:672020.PubMed/NCBI
|
|
23
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rebouissou S and Nault JC: Advances in
molecular classification and precision oncology in hepatocellular
carcinoma. J Hepatol. 72:215–229. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zucman-Rossi J, Villanueva A, Nault JC and
Llovet JM: Genetic landscape and biomarkers of hepatocellular
carcinoma. Gastroenterology. 149:1226–1239.e4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dimri M and Satyanarayana A: Molecular
signaling pathways and therapeutic targets in hepatocellular
carcinoma. Cancers (Basel). 12:4912020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wegiel B, Vuerich M, Daneshmandi S and
Seth P: Metabolic Switch in the tumor microenvironment determines
immune responses to Anti-Cancer therapy. Front Oncol. 8:2842018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ
and Wu C: The correlation of expression levels of HIF-1α and HIF-2α
in hepatocellular carcinoma with capsular migration, portal vein
tumor thrombi and patients' clinical outcome. Jpn J Clin Oncol.
44:159–167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng W, Xue T, Huang S, Shi Q, Tang C, Cui
G, Yang G, Gong H and Guo H: HIF-1α promotes the migration and
migration of hepatocellular carcinoma cells via the IL-8-NF-κB
axis. Cell Mol Biol Lett. 23:262018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feng B, Zhu Y, Su Z, Tang L, Sun C, Li C
and Zheng G: Basil polysaccharide attenuates hepatocellular
carcinoma metastasis in rat by suppressing H3K9me2 histone
methylation under hepatic artery ligation-induced hypoxia. Int J
Biol Macromol. 107:2171–2179. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang M, Zhao X, Zhu D, Liu T, Liang X, Liu
F, Zhang Y, Dong X and Sun B: HIF-1α promoted vasculogenic mimicry
formation in hepatocellular carcinoma through LOXL2 up-regulation
in hypoxic tumor microenvironment. J Exp Clin Cancer Res.
36:602017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Feng J, Dai W, Mao Y, Wu L, Li J, Chen K,
Yu Q, Kong R, Li S, Zhang J, et al: Simvastatin re-sensitizes
hepatocellular carcinoma cells to sorafenib by inhibiting
HIF-1α/PPAR-gamma/PKM2-mediated glycolysis. J Exp Clin Cancer Res.
39:242020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Feng B, Zhu Y, Sun C, Su Z, Tang L, Li C
and Zheng G: Basil polysaccharide inhibits hypoxia-induced
hepatocellular carcinoma metastasis and progression through
suppression of HIF-1α-mediated epithelial-mesenchymal transition.
Int J Biol Macromol. 137:32–44. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seo J, Jeong DW, Park JW, Lee KW, Fukuda J
and Chun YS: Fatty-acid-induced FABP5/HIF-1 reprograms lipid
metabolism and enhances the proliferation of liver cancer cells.
Commun Biol. 3:6382020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang XM, Cao XY, He P, Li J, Feng MX,
Zhang YL, Zhang XL, Wang YH, Yang Q, Zhu L, et al: Overexpression
of Rac GTPase activating protein 1 contributes to proliferation of
cancer cells by reducing hippo signaling to promote cytokinesis.
Gastroenterology. 155:1233–1249.e22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang MY, Chen DP, Qi B, Li MY, Zhu YY, Yin
WJ, He L, Yu Y, Li ZY, Lin L, et al: Pseudogene RACGAP1P activates
RACGAP1/Rho/ERK signalling axis as a competing endogenous RNA to
promote hepatocellular carcinoma early recurrence. Cell Death Dis.
10:4262019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang WH, Forde D and Lai AG: Dual
prognostic role of 2-oxoglutarate-dependent oxygenases in ten
cancer types: Implications for cell cycle regulation and cell
adhesion maintenance. Cancer Commun (Lond). 39:232019.PubMed/NCBI
|
|
39
|
Ozensoy Guler O, Supuran CT and Capasso C:
Carbonic anhydrase IX as a novel candidate in liquid biopsy. J
Enzyme Inhib Med Chem. 35:255–260. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mast JM and Kuppusamy P: Hyperoxygenation
as a therapeutic supplement for treatment of triple negative breast
cancer. Front Oncol. 8:5272018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim MC, Hwang SH, Kim NY, Lee HS, Ji S,
Yang Y and Kim Y: Hypoxia promotes acquisition of aggressive
phenotypes in human malignant mesothelioma. BMC Cancer. 18:8192018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li HS, Zhou YN, Li L, Li SF, Long D, Chen
XL, Zhang JB, Feng L and Li YP: HIF-1α protects against oxidative
stress by directly targeting mitochondria. Redox Biol.
25:1011092019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang X, de Carvalho Ribeiro M,
Iracheta-Vellve A, Lowe P, Ambade A, Satishchandran A, Bukong T,
Catalano D, Kodys K and Szabo G: Macrophage-Specific
hypoxia-inducible factor-1α contributes to impaired autophagic flux
in nonalcoholic steatohepatitis. Hepatology. 69:545–563. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xia YJ, Jiang XT, Jiang SB, He XJ, Luo JG,
Liu ZC, Wang L, Tao HQ and Chen JZ: PHD3 affects gastric cancer
progression by negatively regulating HIF1A. Mol Med Rep.
16:6882–6889. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang J, Xu J, Dong Y and Huang B:
Down-regulation of HIF-1alpha inhibits the proliferation,
migration, and migration of gastric cancer by inhibiting PI3K/AKT
pathway and VEGF expression. Biosci Rep. 38:BSR201807412018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Singh R, Mishra MK and Aggarwal H:
Inflammation, immunity, and cancer. Mediators Inflamm.
2017:60273052017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lawson CD and Der CJ: Filling GAPs in our
knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like
breast cancers. Small GTPases. 9:290–296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang C, Wang W, Liu Y, Yong M, Yang Y and
Zhou H: Rac GTPase activating protein 1 promotes oncogenic
progression of epithelial ovarian cancer. Cancer Sci. 109:84–93.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yin C, Toiyama Y, Okugawa Y, Shigemori T,
Yamamoto A, Ide S, Kitajima T, Fujikawa H, Yasuda H, Okita Y, et
al: Rac GTPase-Activating Protein 1 (RACGAP1) as an oncogenic
enhancer in esophageal carcinoma. Oncology. 97:155–163. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yeh CM, Sung WW, Lai HW, Hsieh MJ, Yen HH,
Su TC, Chang WH, Chen CY, Ko JL, Chen CJ, et al: Opposing
prognostic roles of nuclear and cytoplasmic RACGAP1 expression in
colorectal cancer patients. Hum Pathol. 47:45–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yang Y, Lu H, Chen C, Lyu Y, Cole RN and
Semenza GL: HIF-1 Interacts with TRIM28 and DNA-PK to release
paused RNA polymerase II and activate target gene transcription in
response to hypoxia. Nat Commun. 13:3162022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Smythies JA, Sun M, Masson N, Salama R,
Simpson PD, Murray E, Neumann V, Cockman ME, Choudhry H, Ratcliffe
PJ and Mole DR: Inherent DNA-binding specificities of the HIF-1α
and HIF-2α transcription factors in chromatin. EMBO Rep.
20:e464012019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Song Z, Cao Q, Guo B, Zhao Y, Li X, Lou N,
Zhu C, Luo G, Peng S, Li G, et al: Overexpression of RACGAP1 by
E2F1 promotes neuroendocrine differentiation of prostate cancer by
stabilizing EZH2 expression. Aging Dis. 2023.doi:
10.14336/AD.2023.0202 (Epub ahead of print). View Article : Google Scholar
|
|
55
|
Rashid M, Zadeh LR, Baradaran B, Molavi O,
Ghesmati Z, Sabzichi M and Ramezani F: Up-down regulation of HIF-1α
in cancer progression. Gene. 798:1457962021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jaskiewicz M, Moszynska A, Kroliczewski J,
Cabaj A, Bartoszewska S, Charzyńska A, Gebert M, Dąbrowski M,
Collawn JF and Bartoszewski R: The transition from HIF-1 to HIF-2
during prolonged hypoxia results from reactivation of PHDs and
HIF1A mRNA instability. Cell Mol Biol Lett. 27:1092022. View Article : Google Scholar : PubMed/NCBI
|
